USRE32874E - Plasma-free medium for platelet storage - Google Patents

Plasma-free medium for platelet storage Download PDF

Info

Publication number
USRE32874E
USRE32874E US06/860,894 US86089486A USRE32874E US RE32874 E USRE32874 E US RE32874E US 86089486 A US86089486 A US 86089486A US RE32874 E USRE32874 E US RE32874E
Authority
US
United States
Prior art keywords
iaddend
iadd
defined
plasma
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/860,894
Inventor
Gail A. Rock
George A. Adams
Original Assignee
ROCK GAIL A 270 SANDRIDGE RD ROCKCLIFFE PARK CANADA K1L 5A2
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA414583 priority Critical
Priority to CA000414583A priority patent/CA1216518A/en
Application filed by ROCK GAIL A 270 SANDRIDGE RD ROCKCLIFFE PARK CANADA K1L 5A2 filed Critical ROCK GAIL A 270 SANDRIDGE RD ROCKCLIFFE PARK CANADA K1L 5A2
Assigned to ROCK, GAIL A. reassignment ROCK, GAIL A. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: ADAMS, GEORGE A.
Application granted granted Critical
Publication of USRE32874E publication Critical patent/USRE32874E/en
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/19Platelets; Megacaryocytes

Abstract

Blood platelet concentrate in a plasma-free medium. Method for storage of blood platelets in a plasma-free medium which comprises centrifuging plasma to obtain a platelet pellet, removing the supernatant plasma, and resuspending the platelet pellet in a balanced salt medium. The balanced salt medium in an isotonic solution and may be selected from well known physiologically tolerable salt mediums. Additives to enhance platelet storage can be added to the salt medium.

Description

BACKGROUND OF THE INVENTION

This invention is concerned with a method for the storage of blood platelets in a plasma-free medium. Also described is a platelet concentrate obtained by this method.

Thrombocytopenia means low platelet counts in the circulatory system. Persons with this disease have a tendency to bleed as do hemophiliacs, except that the bleeding is usually from many small capillaries rather than from large vessels as in hemophilia. Such persons suffer small punctate hemorrhages throughout all the body tissues. The skin of such a person will exhibit many small, purplish blotches. Platelets are especially important for repair of minute breaks in capillaries and other small vessels. Platelets aglutinate to fill such ruptures without actually causing clots.

Normally, excessive bleeding does not occur until the number of platelets in the blood falls below a value of approximately 70,000 per cubic millimeter rather than the normal of 150,000 to 350,000.

At the present time, persons who have low platelet counts are supported by infusion of platelet concentrates. Platelet concentrates contain on average 6×1010 platelets suspended in a volume of 50-60 ml of plasma. Larger platelet concentrates can be obtained using apheresis machinery, in which case the concentration is in the range of 4×1011 and the plasma volume may reach 200-300 ml. Platelet concentrates can be kept for 3, 5 or even 7 days, depending on the type of bag and mode of rotation used.

There are generally speaking two types of blood collection and storage bags available. One type permits storage of platelets in plasma for up to 3 days while another type permits storage of platelets in plasma for up to 5 days and sometimes up to 7 days. The latter type is generally used for research purposes. In addition it should be noted that platelet storage bags must not contain the plasticizer di-2-ethyl-hexylphthalate and they should be highly permeable. While stored, all bags are subjected to rotation on a continuous basis which can be rotational about a transverse axis or horizontal and reciprocal or horizontal and circular.

SUMMARY OF THE INVENTION

The present inventors have developed a method whereby platelets can be stored in a medium other than plasma while still retaining the functional characteristics of platelets stored in plasma. The technique involves centrifugation of the plasma to obtain a platelet pellet, removal of the supernatant plasma, and subsequent resuspension of the platelet pellet in a balanced salt medium.

Thus, the present invention provides a method for the preparation of a platelet concentrate which comprises centrifuging plasma to obtain a platelet pellet, removing supernatant plasma and resuspending the platelet pellet in a balanced salt medium.

The plasma can be derived from freshly collected while blood or may be collected using apheresis machinery, i.e. apheresis platelets. The blood or plasma is preferably collected from humans.

The balanced salt medium or isotonic solution is designed to provide the basic nutrients required for platelet support during storage and, as well, to enhance the environment above that obtained under plasma (physiological) conditions. More specifically, the isotonic solution or balanced salt medium comprises a conventional, physiologically tolerable isotonic solution to which various additional additives may be added to enhance platelet stability.

Examples of conventional balanced salt mediums or isotonic solutions which can be used for this purpose are Spinner salt solution (Eagle H, Science, 130:432 (1959)), Tyrode's (Tyrode, M. V., Arch. Intern. Pharmacodyn., 20:205 (1910)), Seligmann balanced salt solution (formula below), Earle's balanced salt solutions (Natl. Cancer. Inst. 4:167 (1943)), Dulbecco's phosphate buffered saline (J. Exp. Med., 98:167 (1954)), Hanks' balanced salt solutions (Proc. Soc. Exp. Biol. Med., 71:196 (1949)), modification-National Institutes of Health) Gey's balanced salt solutions (Amer. J. of Cancer, 27:55 (1936)), Puck's saline (Puck, T. T., Cieciura, S. J. and Robinson, A. J. Exp. Med., 108:945 (1958)).

The formula for Seligmann balanced salt solution is as follows:

______________________________________Component       mg/L______________________________________NaCl            7650.00KCl             200.00NaCO.sub.2.CH.sub.3           1500.00NaH.sub.2 PO.sub.4.H.sub.2 O           50.00KH.sub.2 PO.sub.4           100.00D-Glucose       1000.00NaHCO.sub.3     700.00Ascorbic Acid   3.00______________________________________

There are several advantages to using a balanced salt solution in place of plasma and these are as follows. The plasma can be recovered and can be used for other purposes involving protein fractionation or transfusion to patients. Plasma is an expensive commodity and generally in short supply. Replacement of the plasma as a supernatant for platelet storage would result in considerable saving of plasma (estimated 14,000 liters in Canada alone in 1982) throughout the world.

Another advantage is the possibility of enhancing the storage environment above that generally found for plasma. Platelets are collected into an anticoagulant solution whose pH and biochemical constituents are chosen to enhance red cell preservation and which therefore may not be of optimal composition for platelet storage.

Beside the economic advantages, there are considerable theoretical medical advantages to removal of plasma and resuspension of platelets in a plasma free medium:

i. Removal of plasma components that are potentially harmful to platelets such as glycolytic and proteolytic enzymes that remove membrane glycoproteins and thus cause premature clearance from the circulation;

ii. Reduce the risk of exposure to infectious agent;

iii. Reduced risk of immediate and delayed allergic responses of recipients;

iv. Greater control over environmental conditions, especially pH, ion concentration and volume;

v. Reduced variations in platelet concentrates that would enhance the confidence of physicians in platelet concentrates perhaps leading to therapeutic regimes requiring fewer platelet concentrates per treatment; and

vi. The addition of agents to the storage medium may further improve platelet function after storage or prolong the storage life of platelets.

The agents which can be added to the storage medium can include one or more of the following. Nutrients may be added to the medium, and may be selected from fructose and other sugars, adenine or acetyl CoA. These nutrients are substrates for the glycolytic or proteolytic enzymes on the platelet surface and prevent these enzymes from altering the platelet surface.

Another approach is to inhibit the above and other enzymes with reversible inhibitors that are diluted upon infusion into the circulatory system and hence no longer inhibitory. Examples of these compounds are indomethacin, quinacrine or vitamin E, all of which inhibit platelet activation during storage and perhaps increase storage life.

Yet another method to control platelet activation during storage is to raise cyclic adenosine monophosphate with exogenous prostaglandins E1, D2 or I2 which again have a short half-life in vivo and reversible effects on platelets.

Finally, the artificial medium can be buffered by addition to the medium of a number of agents all of which can safely be infused into patients. These include phosphate and the amino acids: histidine, cysteine, tyrosine, lysine or arginine. These amino acids have the ability to buffer at an alkaline pH of 9 while phosphate precipitates at this pH.

Thus, in summary the isotonic solution may contain nutrients to improve the storage life of the platelets, reversible inhibitors for platelet activation, substances to raise cyclic adenosine monophosphate levels and which have reversible effects on platelets, and buffering agents which can be safely infused into patients. Generally these additives are used in physiological salt concentrations.

By the present method, the storage of platelet concentrates in a plasma free medium can be effected for at least 72 hours and results can be obtained which are similar to or better than those currently found using standard conditions of storage in plasma.

In another aspect, this invention provides a platelet concentrate in a plasma-free medium, which medium is a balanced salt medium which is an isotonic solution. The solution may be modified with the previously described agents. The present platelet concentrates can be stored for the same amount of time as presently available plasma concentrates can be stored. Further the platelet concentrates in the non-plasma medium are about the same as for the plasma medium, that is, about 109 ml or 1012 /L.

DETAILED DESCRIPTION OF THE INVENTION

The following examples are used to illustrate the present invention. All parts and percentages are by weight unless otherwise specified.

Two series of experiments were carried out to show the effects of storing platelets in a non-plasma medium. The first series (A) uses extraction and a washing step to remove plasma from platelets prior to final suspension in a Tyrode's solution. The second series (B) uses only extraction of plasma and final suspension in a modified Tyrode's solution containing either extra phosphate buffer or histidine buffer.

EXAMPLE 1 Series A

Method:

Preparation of Platelet Concentrates: Platelet concentrates were prepared by acidification of a pool of platelet-rich plasma using 35 ml acid-citrate-dextrose anticoagulant to 230 ml of platelet-rich plasma, to yield a final pH of 6.4. This lower pH allows immediate resuspension of platelets concentrated by the normal centrifugation procedure of 3000 g for 5.5 minutes. The plasma was extracted and the platelets resuspended in a washing solution containing 0.5 mM EDTA in calcium and magnesium-free Tyrode's buffer, pH 6.4. After centrifugation at 3000 g for 5.5 minutes and extraction of supernatant, the platelets were resuspended in (Citrate-Phosphate-Dextrose anticoagulant) CPD Tyrode's solution or CPD-plasma at a final volume of 60 ml in P1-146 (plastic) bags (a trademark of Fenwall Company, Deerfield, Ill. 60015). The composition of the CPD-Tyrode's balanced salt solution is given in Table 1. These concentrates were stored at 22° C. in a horizontal shaker for testing after 3 days.

Platelet Aggregation: Aliquots from the platelet concentrates were diluted in pooled plasma containing CPD to a final concentration of 3×108 platelets/μl. After incubating for one hour at 37° the platelet suspensions were aggregated by addition of one stimulus or simultaneous addition of pairs of stimuli. The stimuli and concentrations used were adenosine diphosphate (ADP) at 10-5 M, epinephrine at 5×10-5 M, collagen at 2.4 μg/ml, arachidonic acid at 10-4 M, and calcium ionophore A23187 at 5×10-6 M. All these are final concentrations in the platelet suspensions.

Results:

The results for the platelets washed and resuspended in CPD-Tyrode's (Table 2) and CPD-plasma (Table 3) and for unwashed normal platelet concentrates (Table 4) are presented. The reported values are means and standard errors of at least three determinations except for those aggregations using arachidonate. The platelets stored in CPD-Tyrode's had slightly reduced aggregation responses when compared to the two control preparations stored in CPD-plasma. All three preparations lost the ability to aggregate to collagen, epinephrine or ADP while retaining aggregation response to pairs of stimuli or ionophore. The response to all three preparations were identical when tested before storage, indicating the washing procedure did not acutely alter the platelets (data not shown).

EXAMPLE 2 Series B

Method:

Preparation of Platelet Concentrates: Platelet concentrates were prepared by the normal centrifugation procedure of 3000 g for 5.5 minutes (no ACD was added). The plasma was extracted and the platelets resuspended in CPD-Tyrode's-phosphate solution, CPD-Tyrode's-Histidine (see Table 1 for recipes) or CPD-plasma at a final volume of 60 ml in PL 145 bags. These concentrates were stored at 22° C. in a horizontal shaker for testing after 3 days.

Platelet Aggregation: All aggregations were performed as in Series A.

Results:

The results for the platelets washed and resuspended in CPD-Tyrode's-phosphate (Table 5), and CPD-Tyrode's-Histidine (Table 6) and for unwashed normal platelet concentrates (Table 4) are presented and show values equal to or better than for platelets stored in the usual way in plasma. The reported values are means and standard errors of at least three determinations except for those aggregations using arachidonate. There was no difference between the platelets stored in CPD-Tyrode's-Histidine, CPD-Tyrode's-phosphate and the preparations stored in CPD-plasma. As in Series A, all three preparations lost the ability to aggregate to collagen, epinephrine or ADP while retaining aggregation response to pairs to stimuli or ionophore. The responses of all three preparations were identical when tested before storage, indicating the washing procedure did not significantly alter the platelets (data not shown).

              TABLE 1______________________________________Composition of Some Artificial Mediums Used  CPD-     CPD-Tyrode's-                       CPD-Tyrode's-  Tyrode's Phosphate   Histidine______________________________________NaCl     120    mM      102   mM    102   mMKCl      2.4    mM      2.4   mM    2.4   mMNaHCO.sub.3    22.0   mM      10.0  mM    10.0  mMNaH.sub.2 PO.sub.4    0.4    mM      22.0  mM    --CaCl.sub.2    1.8    mM      1.8   mM    1.8   mMMgCl.sub.2    0.9    mM      0.9   mM    0.9   mMGlucose  22.0   mM      22.0  mM    22.0  mMCitrate  1.0    mM      1.9   mM    1.9   mMTrisodium    10.8   mM      10.8  mM    10.8  mMCitrateNa.sub.2 HPO.sub.4    1.9    mM      1.9   mM    --Histindine    --         --          22.0  mMpH       7.4    mM      7.4   mM    7.4   mMOsmolarity    298    mOsm    303   mOsm  313   mOsm______________________________________

              TABLE 2______________________________________Percent Platelet Aggregation After Storage of Washed Plateletsat 22° C. for 72 hours in CPD-Tyrode's.   First StimulusSecond                                   Arach-Stimulus  Saline  ADP    Epinephrine                             Collagen                                    idonate______________________________________Saline    0ADP       5(2)*Epinephrine     2(3)    24(8)Collagen  1(2)    26(2)  22(18)Arachidonate     18(5)   --     34       --Ionophore 31(8)   29(8)  27(7)    31(9)  --______________________________________ *mean (S.E.) of at least 3 determinations except for aggregations using arachidonate

              TABLE 3______________________________________Percent Platelet Aggregation After Storage of Washed Plateletsat 22° C. for 72 hours in CPD-Plasma.   First StimulusSecond                                   Arach-Stimulus  Saline  ADP    Epinephrine                             Collagen                                    idonate______________________________________Saline    0ADP       8(5)*Epinephrine     1(1)    40(4)Collagen  2(2)    43(3)  47(6)Arachidonate     21(2)   48     46       --Ionophore 40(2)   45(6)  40(4)    47(10) 46______________________________________ *mean (S.E.) of at least 3 determintions except for aggregations using arachidonate

              TABLE 4______________________________________Percent Platelet Aggregation After Storage of UnwashedPlatelets at 22° C. for 72 hours in CPD-Plasma   First StimulusSecond                                   Arach-Stimulus  Saline  ADP    Epinephrine                             Collagen                                    idonate______________________________________Saline    0ADP       14(5)*Epinephrine     0(1)    40(2)Collagen  2(1)    43(2)  41(2)Arachidonate     27(3)   44(2)  43(5)    --Ionophore 47(5)   46(2)  39(2)    46(2)  44______________________________________ *mean (S.E.) of at least 7 determinations except for aggregations using arachidonate which are means of 3 determinations.

              TABLE 5______________________________________Percent Platelet Aggregation After Storage of Washed Plateletsat 22° C. for 72 hours in CPD-Tyrode's-Phosphate.   First StimulusSecond                                   Arach-Stimulus  Saline  ADP    Epinephrine                             Collagen                                    idonate______________________________________Saline    0ADP       7Epinephrine     0       38Collagen  2       47     41Arachidonate     28      40     39       38*Ionophore 40      45     42       46     38*______________________________________

              TABLE 6______________________________________Percent Platelet Aggregation After Storage of Washed Plateletsat 22° C. for 72 Hours in CPD-Tyrode's-Histidine.   First StimulusSecond                                   Arach-Stimulus  Saline  ADP    Epinephrine                             Collagen                                    idonate______________________________________Saline    0ADP       11Epinephrine     1       35Collagen 5     43      33Arachidonate     24*     42*    38*      33*Ionophore +       48     37       43     30*A23187______________________________________ *mean (S.E.) of at least 3 determinations except for aggregation using arachidonate + 2 experiments gave no aggregation with ionophore A23187 while one gave 36% aggregation. Normal platelet aggregation to ionophore A23187 were found in CPDTyrod' sPhosphate.

Claims (35)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A method for the preparation of .[.a.]. .Iadd.an essentially plasma-free .Iaddend.blood platelet concentrate for administration to animals which comprises
centrifuging plasma to obtain a platelet pellet,
removing the supernatant plasma, and
resuspending the platelet pellet in a medium consisting essentially of: a balanced, physiological compatible, saline solution; an anticoagulant; and one or more additives to enhance stability of the platelets selected from (a) nutrients to improve the storage life of the platelets, (b) reversible inhibitors for platelet activation, (c) substances to raise cyclic adenosine monophosphate levels which have reversible effects on platelets, and (d) buffering agents which are physiologically compatible.
2. A method as claimed in claim 1 wherein the nutrients are selected from fructose, adenine or acetyl CoA.
3. A method as claimed in claim 1 wherein the reversible inhibitors for platelet activation are selected from indomethacin, quinacrine or vitamin E.
4. A method as claimed in claim 1 wherein the substances to raise cyclic adenosine monophosphate levels are selected from prostaglandins E1, D2 or I2.
5. A method as claimed in claim 1 wherein the buffering agents are selected from phosphate or amino acids.
6. A method as claimed in claim 5 wherein the amino acids are selected from histidine, cysteine, tyrosine, lysine or arginine.
7. A method as claimed in claim 1 wherein the balanced salt medium is selected from Spinner salt solution, Tyrode's solution, Seligmann's balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solutions or Puck's saline.
8. A method as claimed in claim 1 wherein the balanced salt medium is a Tyrode's solution.
9. A method as claimed in claim 6 wherein the Tyrode's solution contains a phosphate buffer or a histidine buffer.
10. A method as claimed in claim 6 wherein extraction and a washing step is used to remove plasma from platelets prior to final suspension in the Tyrode's solution.
11. A method as claimed in claim 7 wherein extraction is used to remove plasma from platelets prior to final suspension in the modified Tyrode's solution.
12. A method as claimed in claim 1 wherein the plasma is human plasma.
13. A method as claimed in claim 1 wherein the plasma is derived from freshly collected whole blood or by apheresis.
14. A method as claimed in claim 1 wherein the plasma is derived from freshly collected whole human blood or by apheresis on a human donor.
15. A method as claimed in claim 1 wherein the plasma is human plasma.
16. A method as claimed in claim 1 wherein the plasma is derived from freshly collected whole blood or by apheresis.
17. A method as claimed in claim 1 wherein the plasma is derived from freshly collected whole human blood or by apheresis on a human donor.
18. .[.A.]. .Iadd.An essentially plasma-free .Iaddend.platelet concentrate composition for administration to animals comprising blood platelets suspended in a medium consisting essentially of:
a balanced, physiologically compatible, saline solution;
an anticoagulant; and
one or more additives to enhance stability of the platelets selected from (a) nutrients to improve the storage life of the platelets, (b) reversible inhibitors for platelet activation, (c) substances to raise cyclic adenosine monophosphate levels which have reversible effects on platelets, and (d) buffering agents which are physiologically compatible.
19. A platelet concentrate as claimed in claim 18 wherein the nutrients are selected from fructose, adenine or acetyl CoA.
20. A platelet concentrate as claimed in claim 18 wherein the reversible inhibitors for platelet activation are selected from indomethacin, quinacrine or vitamin E.
21. A platelet concentrate as claimed in claim 18 wherein the substances to raise cyclic adenosine monophosphate levels are selected from prostaglandins E1, D2 or I2.
22. A platelet concentrate as claimed in claim 18 wherein the buffering agents are selected from phosphate or amino acids.
23. A platelet concentrate as claimed in claim 22, wherein the amino acids are selected from histidine, cysteine, tyrosine, lysine or arginine.
24. A platelet concentrate as claimed in claim 18, wherein the balanced salt medium is selected from Spinner salt solution, Tyrode's solution, Seligmann's balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solutions or Puck's saline.
25. A platelet concentrate as claimed in claim 18 wherein the balanced salt medium is a Tyrode's solution.
26. A platelet concentrate as claimed in claim 25 wherein the Tyrode's solution contains a phosphate buffer or a histidine buffer.
27. A platelet concentrate as claimed in claim 18 wherein the plasma is human plasma.
28. A platelet concentrate as claimed in claim 18 wherein the human plasma is derived from freshly collected whole blood or by apheresis on a human donor. .Iadd.
29. An essentially plasma-free storage-stable package of blood platelets, which comprises a concentrate of blood platelets suspended in a volume of physiologically acceptable salt solution, said suspension being sealedly enclosed within a blood storage member. .Iaddend. .Iadd.30. The storage-stable package as defined by claim 29 which is devoid of a buffering agent. .Iaddend. .Iadd.31. The storage-stable package as defined by claim 29 which is devoid of an anticoagulant. .Iaddend. .Iadd.32. The storage-stable package as defined by claim 29, said blood storage member comprising a blood collection and storage bag. .Iaddend. .Iadd.33. The storage-stable package as defined by claim 32, said blood collection and storage bag being highly permeable. .Iaddend. .Iadd.34. The storage-stable package as defined by claim 29, said blood storage member comprising a plastic blood collection and storage bag. .Iaddend. .Iadd.35. The storage-stable package as defined by claim 29, which further comprises a buffering agent. .Iaddend. .Iadd.36. The storage-stable package as defined by claim 29, wherein the physiologically compatible salt solution is selected from the group consisting of Spinner salt solution, Tyrode's solution, Seligmann balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solution or Puck's saline. .Iaddend.
.Iadd. 7. The storage-stable package as defined by claim 36, wherein the physiologically compatible salt solution is Tyrode's solution. .Iaddend. .Iadd.38. The storage-stable package as defined by claim 37, wherein Tyrode's solution contains a phosphate buffer or a histidine buffer. .Iaddend. .Iadd.39. The storage-stable package as defined by claim 29, wherein the blood platelets are human blood platelets. .Iaddend. .Iadd.40. The storage-stable package as defined by claim 39, wherein the blood platelets are derived from platelet-rich plasma from whole blood or by apheresis on a human donor. .Iaddend. .Iadd.41. The storage-stable package as defined by claim 29, further comprising an anticoagulant. .Iaddend. .Iadd.42. The storage-stable package as defined by claim 29, further comprising saline-citrate-buffer. .Iaddend. .Iadd.43. The storage-stable package as defined by claim 29, further comprising
saline-citrate-buffer-nutrient. .Iaddend. .Iadd.44. A composition of matter comprising an essentially plasma-free storage-stable concentrate of blood platelets suspended in a volume of physiologically acceptable salt solution, said composition exhibiting no worse than normal platelet aggregation. .Iaddend. .Iadd.45. The composition of matter as defined by claim 44, further comprising an additive adopted to enhance platelet function under conditions of storage, or to prolong the storage life thereof. .Iaddend. .Iadd.46. The composition of matter as defined by claim 45, which said additive is a buffering agent. .Iaddend. .Iadd.47. The composition of matter as defined by claim 44, wherein the physiologically compatible salt solution is selected from the group consisting of Spinner salt solution, Tyrode's solution, Seligmann balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solution or Puck's saline. .Iaddend. .Iadd.48. The composition of matter as defined by claim 47, wherein the physiologically compatible salt solution is Tyrode's
solution. .Iaddend. .Iadd.49. The composition of matter as defined by claim 48, wherein Tyrode's solution contains a phosphate buffer or a histidine buffer. .Iaddend. .Iadd.50. The composition of matter as defined by claim 44, wherein the blood platelets are human blood platelets. .Iaddend. .Iadd.51. The composition of matter as defined by claim 50, wherein the blood platelets are derived from platelet-rich plasma from whole blood or by apheresis on a human donor. .Iaddend. .Iadd.52. The composition of matter as defined by claim 44, further comprising an anticoagulant. .Iaddend. .Iadd.53. The composition of matter as defined by claim 44, further comprising saline-citrate-buffer. .Iaddend. .Iadd.54. The composition of matter as defined by claim 44, further comprising saline-citrate-buffer-nutrient. .Iaddend. .Iadd.55. A method for the storage of essentially plasma-free blood platelets, which comprises confining a concentrate of said blood platelets suspended in a volume of physiologically acceptable salt solution within a blood storage member,
for a period of time of at least 72 hours. .Iaddend. .Iadd.56. The method as defined by claim 55, comprising confining the suspension within said blood storage member under conditions of agitation. .Iaddend. .Iadd.57. The method as defined by claim 55, wherein a buffering agent is contained in the storage member. .Iaddend. .Iadd.58. The method as defined by claim 55, wherein the physiologically compatible salt solution is selected from the group consisting of Spinner salt solution, Tyrode's solution, Seligmann balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solution or Puck's saline. .Iaddend. .Iadd.59. The method as defined by claim 58, wherein the physiologically compatible salt solution is Tyrode's solution. .Iaddend. .Iadd.60. The method as defined by claim 59, wherein Tyrode's solution contains a phosphate buffer or a histidine buffer. .Iaddend. .Iadd.61. The method as defined by claim 55,
wherein the plasma is human plasma. .Iaddend. .Iadd.62. The method as defined by claim 61, wherein the plasma is derived from human whole blood or by apheresis on a human donor. .Iaddend. .Iadd.63. The method as defined by claim 55, wherein the storage member is highly permeable. .Iaddend. .Iadd.64. The method as defined by claim 55, wherein an anticoagulant is contained in the storage member. .Iaddend. .Iadd.65. The method as defined by claim 55, wherein saline-citrate-buffer is present within the storage member. .Iaddend. .Iadd.66. The method as defined by claim 55, wherein saline-citrate-buffer-nutrient is present within the storage member. .Iaddend. .Iadd.67. A method for the treatment of thrombocytopenia in a patient in need of such treatment, which comprises infusing into such patient an effective amount of an essentially plasma-free concentrate of blood platelets suspended in a volume of
physiologically compatible salt solution. .Iaddend. .Iadd.68. The method as defined by claim 67, wherein the physiologically compatible salt solution is selected from the group consisting of Spinner salt solution, Tyrode's solution, Seligmann balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solution or Puck's saline. .Iaddend. .Iadd.69. The method as defined by claim 68, wherein the physiologically compatible salt solution is Tyrode's solution. .Iaddend. .Iadd.70. The method as defined by claim 69, wherein Tyrode's solution contains a phosphate buffer or histidine buffer. .Iaddend.
US06/860,894 1982-11-01 1986-05-08 Plasma-free medium for platelet storage Expired - Lifetime USRE32874E (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA414583 1982-11-01
CA000414583A CA1216518A (en) 1982-11-01 1982-11-01 Plasma-free medium for platelet storage

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06/449,762 Reissue US4447415A (en) 1982-11-01 1982-12-14 Plasma-free medium for platelet storage

Publications (1)

Publication Number Publication Date
USRE32874E true USRE32874E (en) 1989-02-21

Family

ID=4123856

Family Applications (2)

Application Number Title Priority Date Filing Date
US06/449,762 Expired - Lifetime US4447415A (en) 1982-11-01 1982-12-14 Plasma-free medium for platelet storage
US06/860,894 Expired - Lifetime USRE32874E (en) 1982-11-01 1986-05-08 Plasma-free medium for platelet storage

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US06/449,762 Expired - Lifetime US4447415A (en) 1982-11-01 1982-12-14 Plasma-free medium for platelet storage

Country Status (4)

Country Link
US (2) US4447415A (en)
EP (1) EP0108588B1 (en)
CA (1) CA1216518A (en)
DE (1) DE3380112D1 (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008349A1 (en) * 1990-11-07 1992-05-29 Baxter International Inc. Blood platelet storage medium
US5147776A (en) * 1990-02-26 1992-09-15 University Of Iowa Research Foundation Use of 2,5-anhydromannitol for control of pH during blood storage
US5234808A (en) * 1991-10-30 1993-08-10 Thomas Jefferson University Acetate addition to platelets stored in plasma
WO1994002015A1 (en) * 1992-07-24 1994-02-03 Montefiore Medical Center Method of preserving platelets
US5344752A (en) * 1991-10-30 1994-09-06 Thomas Jefferson University Plasma-based platelet concentrate preparations
US5376524A (en) * 1991-04-01 1994-12-27 Thomas Jefferson University Platelet storage medium containing acetate and phosphate
US5459030A (en) * 1992-03-02 1995-10-17 Steritech, Inc. Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5474891A (en) * 1991-10-30 1995-12-12 Thomas Jefferson University Plasma-based platelet concentrate preparations with additive
US5482828A (en) * 1992-03-02 1996-01-09 Steritech, Inc. Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5569579A (en) * 1991-04-01 1996-10-29 Thomas Jefferson University Synthetic-based platelet storage media
US5589395A (en) * 1989-12-20 1996-12-31 Behringwerke Aktiengesellschaft Method for stabilizing annexins
US5618662A (en) * 1992-03-02 1997-04-08 Cerus Corporation Intravenous administration of psoralen
US5709991A (en) * 1992-03-02 1998-01-20 Cerus Corporation Proralen inactivation of microorganisms and psoralen removal
WO1998056247A1 (en) * 1997-06-09 1998-12-17 Baxter International Inc. Platelet suspensions and methods for resuspending platelets
US5906915A (en) * 1990-11-07 1999-05-25 Baxter International Inc. Method for storing red cells using reduced citrate anticoagulant and a solution containing sodium, citrate, phosphate, adenine and mannitol
US6251580B1 (en) 1992-03-02 2001-06-26 Lily Lin Synthetic media for blood components
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US6277556B1 (en) 1994-12-16 2001-08-21 Baxter International Inc. Controlling donor blood characteristics
US6277337B1 (en) 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US6413713B1 (en) * 1998-10-30 2002-07-02 Hyperbaric Systems Method for preserving blood platelets
US6548241B1 (en) 2000-11-28 2003-04-15 Gambro, Inc. Storage solution containing photosensitizer for inactivation of biological contaminants
US20030201160A1 (en) * 2002-04-24 2003-10-30 Gambro, Inc. Removal of adenine during a process of pathogen reducing blood and blood components
US20040081956A1 (en) * 2000-06-02 2004-04-29 Gambro, Inc. Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US20050019917A1 (en) * 2003-04-23 2005-01-27 Human Biosystems Methods and solutions for storing donor organs
US20050282143A1 (en) * 1998-07-21 2005-12-22 Gambro, Inc. Use of visible light at wavelengths of 500 nm and higher to pathogen reduce blood and blood components
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US20070099170A1 (en) * 1998-07-21 2007-05-03 Navigant Biotechnologies, Inc. Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate
US20070098697A1 (en) * 2000-06-02 2007-05-03 Navigant Biotechnologies, Inc. Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US20080107636A1 (en) * 2000-06-02 2008-05-08 Navigant Biotechnologies, Llc Induction of and Maintenance of Nucleic Acid Damage in Pathogens Using Riboflavin and Light
US20080299538A1 (en) * 2003-02-28 2008-12-04 Caridianbct Biotechnologies, Llc Pathogen Inactivation of Whole Blood
US20090023130A1 (en) * 2003-02-28 2009-01-22 Caridianbct Biotechnologies, Llc Prevention of Transfusion Related Acute Lung Injury Using Riboflavin and Light
US20090191537A1 (en) * 2007-12-20 2009-07-30 Veronique Mayaudon Medium and methods for the storage of platelets
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US9168281B2 (en) 2011-03-09 2015-10-27 Charles E. Worden, SR. Kit for treating a wound
US9402866B2 (en) 2011-04-07 2016-08-02 Fenwal, Inc. Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992363A (en) * 1983-11-09 1991-02-12 Thomas Jefferson University Method for preparing glucose free media for storing blood platelets
US4828976A (en) * 1983-12-29 1989-05-09 Thomas Jefferson University Glucose free media for storing blood platelets
AT82500T (en) * 1984-06-22 1992-12-15 Richard L Veech Electrolyte solutions and their use (in vivo).
AT84066T (en) * 1984-06-22 1993-01-15 Richard L Veech Electrolyte solutions and their in vitro use.
US4695460A (en) * 1986-03-19 1987-09-22 American Red Cross Synthetic, plasma-free, transfusible platelet storage medium
US5248506A (en) * 1986-03-19 1993-09-28 American National Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US4961928A (en) * 1986-03-19 1990-10-09 American Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
IT1217938B (en) * 1988-06-28 1990-03-30 Girolamo Sirchia Prepn. and storage of platelet concentrates from buffy-coats
US4994367A (en) * 1988-10-07 1991-02-19 East Carolina University Extended shelf life platelet preparations and process for preparing the same
US5573940A (en) * 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US4925665A (en) * 1989-06-22 1990-05-15 Thomas Jefferson University Glucose free primary anticoagulant for blood containing citrate ions
US5316674A (en) * 1989-09-12 1994-05-31 Pall Corporation Device for processing blood for human transfusion
US5152905A (en) * 1989-09-12 1992-10-06 Pall Corporation Method for processing blood for human transfusion
US5236716A (en) * 1990-02-12 1993-08-17 Miles Inc. Platelets concentrate with low white blood cells content
US5089146A (en) 1990-02-12 1992-02-18 Miles Inc. Pre-storage filtration of platelets
US5919614A (en) * 1994-10-19 1999-07-06 Lifecell Corporation Composition comprising three platelet lesion inhibitors for platelet storage
US6221669B1 (en) 1994-10-19 2001-04-24 Lifecell Corporation Prolonged preservation of blood platelets
US5622867A (en) * 1994-10-19 1997-04-22 Lifecell Corporation Prolonged preservation of blood platelets
US7166568B1 (en) 1998-02-09 2007-01-23 Oklahoma Medical Research Foundation Compositions and methods to inhibit formation of the C5b-9 complex of complement
JP4892133B2 (en) 1999-04-12 2012-03-07 ハーベスト・テクノロジーズ・コーポレイション Method for producing a platelet-rich plasma and / or platelet concentrates
DE60016034T2 (en) 1999-12-21 2005-12-01 Ericson, Daniel G., Rochester Composition for the storage of platelets
US7264608B2 (en) * 2001-12-05 2007-09-04 Fenwal, Inc. Manual processing systems and methods for providing blood components conditioned for pathogen inactivation
US7241282B2 (en) * 2002-11-08 2007-07-10 The Brigham And Women's Hospital, Inc. Compositions and methods for prolonging survival of platelets
US20040229205A1 (en) * 2003-05-16 2004-11-18 Ericson Daniel G. Compositions for the storage of platelets
BRPI0415752A (en) 2003-10-22 2006-12-19 Hutchinson Fred Cancer Res methods, compositions and devices for inducing stasis in cells, tissues, organs and organisms
KR100689516B1 (en) * 2004-09-15 2007-03-02 삼성전자주식회사 Method and apparatus for indicating preferred layer information in multimedia broadcast/multicast system
EP1929289B1 (en) 2005-09-26 2018-02-21 Lifecell Corporation Dry platelet composition
EP2170356A1 (en) 2007-06-25 2010-04-07 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2786014A (en) * 1952-09-10 1957-03-19 James L Tullis Platelet preservation
GB1014712A (en) * 1963-05-31 1965-12-31 Union Carbide Corp Improvements in and relating to liquid media in contact with animal cells
US3629071A (en) * 1970-02-10 1971-12-21 Upjohn Co Storage-stable hemostatic transfusion suspensions of blood platelets, glucose, magnesium chloride and certain prostaglandins
GB1283273A (en) * 1970-11-05 1972-07-26 Amicon Corp Process and apparatus for blood fractionation
US3729947A (en) * 1970-12-04 1973-05-01 Alza Corp Process for storing blood platelets
US3735005A (en) * 1970-08-19 1973-05-22 Alza Corp Method for preparing a viable platelet concentrate
US3753357A (en) * 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US3814687A (en) * 1973-06-01 1974-06-04 Honeywell Inc Blood platelet separation
US3850174A (en) * 1973-03-14 1974-11-26 Becton Dickinson Co Plasma separator assembly
US4014993A (en) * 1975-10-15 1977-03-29 The Upjohn Company Inhibition of platelet aggregation with substituted phenylhydratropic acid compounds
US4061537A (en) * 1975-07-18 1977-12-06 Behringwerke Aktiengesellschaft Polyionic isotonic salt solution
US4148879A (en) * 1977-12-23 1979-04-10 Nelson Research & Development Company Inhibition of platelet aggregation with selected phosphonic and phosphinic acid esters
US4152208A (en) * 1977-03-29 1979-05-01 Hoffmann-La Roche Inc. Stabilized leucocytes
US4267269A (en) * 1980-02-05 1981-05-12 Baxter Travenol Laboratories, Inc. Red cell storage solution
US4269718A (en) * 1980-05-05 1981-05-26 The Institutes Of Medical Sciences Process and device for centrifugal separation of platelets
US4387031A (en) * 1980-07-22 1983-06-07 Luigi Prandi Compositions able to separate the erythrocytes from the serum or plasma in blood analysis samples, and the method which uses them
US4390619A (en) * 1981-09-28 1983-06-28 James Clifford Haight Leukocyte or platelet storage using ion-exchange resins
US4405719A (en) * 1981-05-29 1983-09-20 Coulter Electronics, Inc. Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures
US4455299A (en) * 1981-11-20 1984-06-19 Baxter Travenol Laboratories, Inc. Storage of blood platelets

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2786014A (en) * 1952-09-10 1957-03-19 James L Tullis Platelet preservation
GB1014712A (en) * 1963-05-31 1965-12-31 Union Carbide Corp Improvements in and relating to liquid media in contact with animal cells
US3629071A (en) * 1970-02-10 1971-12-21 Upjohn Co Storage-stable hemostatic transfusion suspensions of blood platelets, glucose, magnesium chloride and certain prostaglandins
US3735005A (en) * 1970-08-19 1973-05-22 Alza Corp Method for preparing a viable platelet concentrate
GB1283273A (en) * 1970-11-05 1972-07-26 Amicon Corp Process and apparatus for blood fractionation
US3729947A (en) * 1970-12-04 1973-05-01 Alza Corp Process for storing blood platelets
US3753357A (en) * 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US3850174A (en) * 1973-03-14 1974-11-26 Becton Dickinson Co Plasma separator assembly
US3814687A (en) * 1973-06-01 1974-06-04 Honeywell Inc Blood platelet separation
US4061537A (en) * 1975-07-18 1977-12-06 Behringwerke Aktiengesellschaft Polyionic isotonic salt solution
US4014993A (en) * 1975-10-15 1977-03-29 The Upjohn Company Inhibition of platelet aggregation with substituted phenylhydratropic acid compounds
US4152208A (en) * 1977-03-29 1979-05-01 Hoffmann-La Roche Inc. Stabilized leucocytes
US4148879A (en) * 1977-12-23 1979-04-10 Nelson Research & Development Company Inhibition of platelet aggregation with selected phosphonic and phosphinic acid esters
US4267269A (en) * 1980-02-05 1981-05-12 Baxter Travenol Laboratories, Inc. Red cell storage solution
US4269718A (en) * 1980-05-05 1981-05-26 The Institutes Of Medical Sciences Process and device for centrifugal separation of platelets
US4387031A (en) * 1980-07-22 1983-06-07 Luigi Prandi Compositions able to separate the erythrocytes from the serum or plasma in blood analysis samples, and the method which uses them
US4405719A (en) * 1981-05-29 1983-09-20 Coulter Electronics, Inc. Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures
US4390619A (en) * 1981-09-28 1983-06-28 James Clifford Haight Leukocyte or platelet storage using ion-exchange resins
US4455299A (en) * 1981-11-20 1984-06-19 Baxter Travenol Laboratories, Inc. Storage of blood platelets

Non-Patent Citations (53)

* Cited by examiner, † Cited by third party
Title
Abrahamsen, A. F., "A Modification of the Technique for 51 Cr-Labelling of Blood Platelets Giving Increased Circulating Platelet Radioactivity", Scand. J. Haemat. (1968), vol. 5, pp. 53-63.
Abrahamsen, A. F., A Modification of the Technique for 51 Cr Labelling of Blood Platelets Giving Increased Circulating Platelet Radioactivity , Scand. J. Haemat. (1968), vol. 5, pp. 53 63. *
Adams, G. A. et al., "Serotonin Uptake by Stored Platelets", Thrombosis Research, (1982), vol. 28, pp. 281-284.
Adams, G. A. et al., Serotonin Uptake by Stored Platelets , Thrombosis Research, (1982), vol. 28, pp. 281 284. *
Browdie, P. et al., "Stroma-Free Hemoglobin--Simplified Preparation and In Vivo and In Vitro Effects on Coagulation in Rabbits", The American Journal of Surgery, (1975), vol. 129, pp. 365-368.
Browdie, P. et al., Stroma Free Hemoglobin Simplified Preparation and In Vivo and In Vitro Effects on Coagulation in Rabbits , The American Journal of Surgery, (1975), vol. 129, pp. 365 368. *
CA 77:59601q B. L. Tranum et al.: In vivo Survival of Platelets Prepared in CPD Anticoagulant, Transfusion, (1972), 12(3):168 74. *
CA 77:59601q--B. L. Tranum et al.: "In vivo Survival of Platelets Prepared in CPD Anticoagulant," Transfusion, (1972), 12(3):168-74.
CA 94:448 728 E. P. Scott et al.: Viability and Function of Platelet Concentrates Stored in CPD Adenine (CPDA 1) , Transfusion, (1980), 20(J):489 97. *
CA 94:448 728--E. P. Scott et al.: "Viability and Function of Platelet Concentrates Stored in CPD-Adenine (CPDA-1)", Transfusion, (1980), 20(J):489-97.
Chemical Abstracts 94:52751f, vol. 94, p. 356, (1981). *
Definition of Ringer s Injection, Ringer s Solution, Lactated Ringer s Injection, Anticoagulant Sodium Citrate Solution, Anticoagulant Acid and Citrate Dextrose Solution. *
Definition of Ringer's Injection, Ringer's Solution, Lactated Ringer's Injection, Anticoagulant Sodium Citrate Solution, Anticoagulant Acid and Citrate Dextrose Solution.
Holme, S. et al., "Comparative Measurements of Platelet Size by Coulter Counter, Microscopy of Blood Smears, and Light-Transmission Studies", J. Lab. Clin. Med., (1981), vol. 97, No. 5, pp. 610-622.
Holme, S. et al., "Platelet Storage at 22° C.: Effect of Type of Agitation on Morphology, Viability, and Function In Vitro", Blood, (1978), vol. 52, No. 2, pp. 425-435.
Holme, S. et al., Comparative Measurements of Platelet Size by Coulter Counter, Microscopy of Blood Smears, and Light Transmission Studies , J. Lab. Clin. Med., (1981), vol. 97, No. 5, pp. 610 622. *
Holme, S. et al., Platelet Storage at 22 C.: Effect of Type of Agitation on Morphology, Viability, and Function In Vitro , Blood, (1978), vol. 52, No. 2, pp. 425 435. *
Kuchler, R. J., "Biochemical Methods in Cell Culture and Virology", (1977), published by Dowden, Hutchinson & Ross, Inc., pp. 83-90.
Kuchler, R. J., Biochemical Methods in Cell Culture and Virology , (1977), published by Dowden, Hutchinson & Ross, Inc., pp. 83 90. *
Kunicki, T. J. et al., "A Study of Variables Affecting the Quality of Platelets Stored at `Room Temperature`", Transfusion, (1975), vol. 15, No. 5, pp. 414-421.
Kunicki, T. J. et al., A Study of Variables Affecting the Quality of Platelets Stored at Room Temperature , Transfusion, (1975), vol. 15, No. 5, pp. 414 421. *
Lazzlo, J., "Energy Metabolism of Human Leukemic Lymphocytes and Granulocytes", Blood, (1967), vol. 30, No. 2, pp. 151-167.
Lazzlo, J., Energy Metabolism of Human Leukemic Lymphocytes and Granulocytes , Blood, (1967), vol. 30, No. 2, pp. 151 167. *
Matsumoto Chem. Abst., vol. 91, (1979), p. 136,650y. *
Matsumoto--Chem. Abst., vol. 91, (1979), p. 136,650y.
Murphy, S. et al., "Platelet Size and Kinetics in Hereditary and Acquired Thrombocytopenia", New England Journal of Medicine, (1972), vol. 286, pp. 499-504.
Murphy, S. et al., "Platelet Storage at 22° C.: Role of Gas Transport Across Plastic Containers in Maintenance of Viability", Blood, (1975), vol. 46, No. 2, pp. 209-218.
Murphy, S. et al., "Storage of Platelet Concentrates at 22° C.", Blood, (1970), vol. 35, No. 4, pp. 549-557.
Murphy, S. et al., Platelet Size and Kinetics in Hereditary and Acquired Thrombocytopenia , New England Journal of Medicine, (1972), vol. 286, pp. 499 504. *
Murphy, S. et al., Platelet Storage at 22 C.: Role of Gas Transport Across Plastic Containers in Maintenance of Viability , Blood, (1975), vol. 46, No. 2, pp. 209 218. *
Murphy, S. et al., Storage of Platelet Concentrates at 22 C. , Blood, (1970), vol. 35, No. 4, pp. 549 557. *
Murphy, S., "Platelet Transfusion", Prog. Hemostasis Thromb., (1976), vol. 3, pp. 289-310.
Murphy, S., "The Preparation and Storage of Platelets for Transfusions", Treatment of Bleeding Disorders by Mammen, Barnhart, Lusher and Walsh, (1980), pp. 303-313.
Murphy, S., Platelet Transfusion , Prog. Hemostasis Thromb., (1976), vol. 3, pp. 289 310. *
Murphy, S., The Preparation and Storage of Platelets for Transfusions , Treatment of Bleeding Disorders by Mammen, Barnhart, Lusher and Walsh, (1980), pp. 303 313. *
Reitzer, L. J. et al., "Evidence That Glutamine, Not Sugar is the Major Energy Source for Cultured HeLa Cells", J. Biol. Chem., (1979), vol. 254, No. 8, pp. 2669-2676.
Reitzer, L. J. et al., "The Pentose Cycle", J. Biol. Chem., (1980), vol. 255, No. 12, pp. 5616-5626.
Reitzer, L. J. et al., Evidence That Glutamine, Not Sugar is the Major Energy Source for Cultured HeLa Cells , J. Biol. Chem., (1979), vol. 254, No. 8, pp. 2669 2676. *
Reitzer, L. J. et al., The Pentose Cycle , J. Biol. Chem., (1980), vol. 255, No. 12, pp. 5616 5626. *
Rock, G. A. et al., "Storage of Platelets Collected by Apheresis", Transfusion, (1983), vol. 23, No. 2, pp. 99-105.
Rock, G. A. et al., Storage of Platelets Collected by Apheresis , Transfusion, (1983), vol. 23, No. 2, pp. 99 105. *
Rock, G. et al., "Platelet Storage: An Assessment of the Requirements for Plasma and Oxygen", Transfusion, (1981), vol. 21, No. 2, pp. 167-177.
Rock, G. et al., "Storage of Platelets Obtained by Apheresis Techniques", Plasma Ther. Transfrs. Technol., (1982), vol. 3, pp. 305-308.
Rock, G. et al., Platelet Storage: An Assessment of the Requirements for Plasma and Oxygen , Transfusion, (1981), vol. 21, No. 2, pp. 167 177. *
Rock, G. et al., Storage of Platelets Obtained by Apheresis Techniques , Plasma Ther. Transfrs. Technol., (1982), vol. 3, pp. 305 308. *
Sivertsen Chem. Abst., vol. 77, (1972), p. 73201r. *
Sivertsen--Chem. Abst., vol. 77, (1972), p. 73201r.
Tegos, C. et al., "Platelet Glycolysis in Platelet Storage--III; The Inability of Platelets to Utilize Exogenous Citrate".
Tegos, C. et al., Platelet Glycolysis in Platelet Storage III; The Inability of Platelets to Utilize Exogenous Citrate . *
Wise, B. M. et al., "The Continuous Growth of Vertebrate Cells in the Absence of Sugar", J. Biol. Chem., (1981), vol. 256, No. 15, pp. 7812-7819.
Wise, B. M. et al., The Continuous Growth of Vertebrate Cells in the Absence of Sugar , J. Biol. Chem., (1981), vol. 256, No. 15, pp. 7812 7819. *
Wong, S. C. et al., "The Effect of Adenine on Platelet Storage", Transfusion, (1982), vol. 22, No. 4, pp. 283-287.
Wong, S. C. et al., The Effect of Adenine on Platelet Storage , Transfusion, (1982), vol. 22, No. 4, pp. 283 287. *

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589395A (en) * 1989-12-20 1996-12-31 Behringwerke Aktiengesellschaft Method for stabilizing annexins
US5147776A (en) * 1990-02-26 1992-09-15 University Of Iowa Research Foundation Use of 2,5-anhydromannitol for control of pH during blood storage
WO1992008349A1 (en) * 1990-11-07 1992-05-29 Baxter International Inc. Blood platelet storage medium
EP0510185A1 (en) * 1990-11-07 1992-10-28 Baxter Int Blood platelet storage medium.
EP0510185B1 (en) * 1990-11-07 1996-12-11 Baxter International Inc. Blood platelet storage medium
US5906915A (en) * 1990-11-07 1999-05-25 Baxter International Inc. Method for storing red cells using reduced citrate anticoagulant and a solution containing sodium, citrate, phosphate, adenine and mannitol
US5569579A (en) * 1991-04-01 1996-10-29 Thomas Jefferson University Synthetic-based platelet storage media
US5376524A (en) * 1991-04-01 1994-12-27 Thomas Jefferson University Platelet storage medium containing acetate and phosphate
US5466573A (en) * 1991-04-01 1995-11-14 Thomas Jefferson University Platelet storage method in a medium containing acetate and phosphate
US5344752A (en) * 1991-10-30 1994-09-06 Thomas Jefferson University Plasma-based platelet concentrate preparations
US5474891A (en) * 1991-10-30 1995-12-12 Thomas Jefferson University Plasma-based platelet concentrate preparations with additive
US5234808A (en) * 1991-10-30 1993-08-10 Thomas Jefferson University Acetate addition to platelets stored in plasma
US20030194806A1 (en) * 1992-03-02 2003-10-16 Lily Lin Synthetic media for blood components
US6866992B2 (en) * 1992-03-02 2005-03-15 Baxter International Inc. Synthetic platelet storage media formulation
US5482828A (en) * 1992-03-02 1996-01-09 Steritech, Inc. Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5618662A (en) * 1992-03-02 1997-04-08 Cerus Corporation Intravenous administration of psoralen
US5709991A (en) * 1992-03-02 1998-01-20 Cerus Corporation Proralen inactivation of microorganisms and psoralen removal
US5459030A (en) * 1992-03-02 1995-10-17 Steritech, Inc. Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US6251580B1 (en) 1992-03-02 2001-06-26 Lily Lin Synthetic media for blood components
US6566046B2 (en) 1992-03-02 2003-05-20 Baxter International Inc. Synthetic media for blood components
US5378601A (en) * 1992-07-24 1995-01-03 Montefiore Medical Center Method of preserving platelets with apyrase and an antioxidant
WO1994002015A1 (en) * 1992-07-24 1994-02-03 Montefiore Medical Center Method of preserving platelets
US6277556B1 (en) 1994-12-16 2001-08-21 Baxter International Inc. Controlling donor blood characteristics
US6613566B2 (en) 1997-06-09 2003-09-02 Baxter International Inc. Platelet suspensions and methods for resuspending platelets
AU738348B2 (en) * 1997-06-09 2001-09-13 Fenwal, Inc. Platelet suspensions and methods for resuspending platelets
US6326197B1 (en) 1997-06-09 2001-12-04 Baxter International Inc. Platelet suspensions and methods for resuspending platelets
WO1998056247A1 (en) * 1997-06-09 1998-12-17 Baxter International Inc. Platelet suspensions and methods for resuspending platelets
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US6277337B1 (en) 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US20070099170A1 (en) * 1998-07-21 2007-05-03 Navigant Biotechnologies, Inc. Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate
US20050282143A1 (en) * 1998-07-21 2005-12-22 Gambro, Inc. Use of visible light at wavelengths of 500 nm and higher to pathogen reduce blood and blood components
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US6413713B1 (en) * 1998-10-30 2002-07-02 Hyperbaric Systems Method for preserving blood platelets
US20040223957A1 (en) * 1998-10-30 2004-11-11 Lucas David O. Compositions, methods and apparatuses for preserving platelets
US7202020B2 (en) 1998-10-30 2007-04-10 Human Biosystems Compositions, methods and apparatuses for preserving platelets
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US6828323B2 (en) 1999-10-19 2004-12-07 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US20070098697A1 (en) * 2000-06-02 2007-05-03 Navigant Biotechnologies, Inc. Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US20100080781A1 (en) * 2000-06-02 2010-04-01 Caridianbct Biotechnologies, Llc Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion
US7892535B2 (en) 2000-06-02 2011-02-22 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US7901673B2 (en) 2000-06-02 2011-03-08 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US7985588B2 (en) 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US20040081956A1 (en) * 2000-06-02 2004-04-29 Gambro, Inc. Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US20080107636A1 (en) * 2000-06-02 2008-05-08 Navigant Biotechnologies, Llc Induction of and Maintenance of Nucleic Acid Damage in Pathogens Using Riboflavin and Light
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US6548241B1 (en) 2000-11-28 2003-04-15 Gambro, Inc. Storage solution containing photosensitizer for inactivation of biological contaminants
US20070148630A1 (en) * 2002-04-24 2007-06-28 Gambro, Inc. Removal of Adenine During a Pathogen Reduction Process in Whole Blood or Red Blood Cells by Dilution
US8679736B2 (en) 2002-04-24 2014-03-25 Terumo Bct Biotechnologies, Llc Removal of adenine during a pathogen reduction process in whole blood or red blood cells by dilution
US20030201160A1 (en) * 2002-04-24 2003-10-30 Gambro, Inc. Removal of adenine during a process of pathogen reducing blood and blood components
US20100089840A1 (en) * 2002-04-24 2010-04-15 Caridianbct Biotechnologies, Llc Removal of Adenine During A Pathogen Reduction Process in Whole Blood or Red Blood Cells by Dilution
US7183045B2 (en) 2002-04-24 2007-02-27 Gambro Inc. Removal of adenine during a pathogen reduction process in whole blood or red blood cell by dilution
US20080299538A1 (en) * 2003-02-28 2008-12-04 Caridianbct Biotechnologies, Llc Pathogen Inactivation of Whole Blood
US20090023130A1 (en) * 2003-02-28 2009-01-22 Caridianbct Biotechnologies, Llc Prevention of Transfusion Related Acute Lung Injury Using Riboflavin and Light
US7029839B2 (en) 2003-04-23 2006-04-18 Human Biosystems Methods and solutions for storing donor organs
US20060121438A1 (en) * 2003-04-23 2006-06-08 Human Biosystems Methods and solutions for storing donor organs
US20050019917A1 (en) * 2003-04-23 2005-01-27 Human Biosystems Methods and solutions for storing donor organs
US20090191537A1 (en) * 2007-12-20 2009-07-30 Veronique Mayaudon Medium and methods for the storage of platelets
US8835104B2 (en) 2007-12-20 2014-09-16 Fenwal, Inc. Medium and methods for the storage of platelets
US9168281B2 (en) 2011-03-09 2015-10-27 Charles E. Worden, SR. Kit for treating a wound
US10273456B2 (en) 2011-04-07 2019-04-30 Fenwal, Inc. Automated methods and systems for washing platelet concentrates
US9402866B2 (en) 2011-04-07 2016-08-02 Fenwal, Inc. Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates

Also Published As

Publication number Publication date
EP0108588A3 (en) 1985-11-06
CA1216518A (en) 1987-01-13
US4447415A (en) 1984-05-08
EP0108588B1 (en) 1989-06-28
DE3380112D1 (en) 1989-08-03
EP0108588A2 (en) 1984-05-16
CA1216518A1 (en)

Similar Documents

Publication Publication Date Title
Rubenberg et al. Microangiopathic haemolytic anaemia: the experimental production of haemolysis and red‐cell fragmentation by defibrination in vivo
Verdier et al. Adenine in blood preservation: Posttransfusion viability and biochemical changes
Owren Coronary thrombosis: its mechanism and possible prevention by linolenic acid
Weiss A study of the cation-and pH-dependent stability of factors V and VIII in plasma
US5474891A (en) Plasma-based platelet concentrate preparations with additive
EP0813361B1 (en) Cryopreservation solution
US5906915A (en) Method for storing red cells using reduced citrate anticoagulant and a solution containing sodium, citrate, phosphate, adenine and mannitol
EP1339279B1 (en) Evaluation and preservation solution
JP4303786B2 (en) Extension method effective shelf life of frozen red blood cells by oxygen removal
Haynes et al. Clinical use of glycerolized frozen blood
EP0187816B1 (en) Prolonged storage of red blood cells
US5800978A (en) Method of freezing cells and cell-like materials
US20040265293A1 (en) Therapeutic platelets and method
US5789151A (en) Prolonged cold storage of red blood cells by oxygen removal and additive usage
AU619224B2 (en) Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US5073492A (en) Synergistic composition for endothelial cell growth
Pietersz et al. Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation
US5344752A (en) Plasma-based platelet concentrate preparations
US4476221A (en) Protective solution for preserving functional cells
Blaschko et al. Observations on the intracellular granules of the adrenal medulla
US5043261A (en) Lyophilized and reconstituted red blood cell and hemosome compositions
US5405742A (en) Solutions for tissue preservation and bloodless surgery and methods using same
US6960428B2 (en) Storage and maintenance of platelets
EP2277594B1 (en) Lysis / resealing process and device for incorporating an active ingredient in erythrocytes
US4356172A (en) Erythrocyte preservative and blood products for long-term storage

Legal Events

Date Code Title Description
AS Assignment

Owner name: ROCK, GAIL A., 270 SANDRIDGE RD., ROCKCLIFFE PARK,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:ADAMS, GEORGE A.;REEL/FRAME:004969/0252

Effective date: 19860502

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12